These insights could inform therapies aimed at reducing metastasis and improving patient outcomes.

A new framework uses organoid-based, in vivo screening to dissect the genetic basis of metastasis in colorectal cancer and potentially other cancers, bridging organoid models with live validation.

The study employs large-scale CRISPR-based screens on organoids embedded in their native tissue and assessed for metastasis in vivo, evaluating both primary tumor growth and metastatic spread.

Through this approach, researchers identified metastasis-suppressing genes, including CTNNA1 and BCL2L13, shedding light on how cell adhesion and cell death pathways influence dissemination.

The findings point toward potential therapeutic strategies that preserve CTNNA1 function or modulate BCL2L13-related cell death to curb metastasis.

CTNNA1 appears to suppress metastasis by maintaining cell–cell adhesion, with loss of CTNNA1 linked to increased invasion and detachment of cancer cells.

The work underscores the importance of gene suppression in metastatic processes and outlines directions for further validation in clinical contexts.

A Penn Vet-led team identified CTNNA1 and BCL2L13 as two metastasis-suppressing genes in preclinical colorectal cancer models.

BCL2L13 promotes a death pathway that helps eliminate detached epithelial cells, suggesting metastasis may rely on downregulating this gene to survive after leaving the primary tumor.

The research is anchored at the University of Pennsylvania, with broader implications spanning genetics and veterinary medicine.

Future directions include screening for metastasis-promoting genes and exploring CRISPR activation or druggable target libraries to expand understanding of metastatic regulators.

Overall, the study offers a novel lens on the genetic factors that prevent cancer cells from spreading and points to new targets for limiting colorectal cancer metastasis.